- Maintains normal, healthy intestinal microflora
- Supports healthy GI immune function
- Supports healthy bowel function
- Supports cytokine balance
- 4 billion CFUs
A pharmaceutical-grade probiotic containing two well-characterized strains of Lactobacillus: L. helveticus R-52† and L. rhamnosus R-11. Some of the mechanisms observed using L. helveticus R-52 and L. rhamnosus R-11 include the production of inhibitory substances (e.g., lactic acid, bacteriocins) and competition for epithelial cell adhesion, both of which help good bacteria predominate. This, in turn, contributes to the stimulation of mucus production, the reduction of microbial toxins, the support of host digestion, and an effect on corticosterone levels and cytokine production.
Research suggests that this formula also downregulates IL-1beta, IL-8, and TNF-alpha . These varied mechanisms help preserve the health, integrity, and function of the gastrointestinal (GI) tract at both the cellular and system levels. Numerous clinical trials employing double-blind, randomized, placebo-controlled techniques have been performed with this formula. The majority of these studies investigated the formula’s role in affecting host intestinal flora and gastrointestinal health. For instance, studies completed on children demonstrated that it helps reduce bacterial toxin load and supports gastrointestinal health [5,6]. Large-scale studies have supported the role of the formula as an adjunct therapy in promoting GI health and healthy bowel function [6,7]
- Johnson-Henry KC, Mitchell DJ, Avitzur Y, et al. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci. 2004 Aug;49(7-8):1095-102. [PMID:15387328]
- Johnson-Henry KC, Nadjafi M, Avitzur Y, et al. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis. 2005 Jun 15;191(12):2106-17. [PMID: 15897997]
- Zareie M, Johnson-Henry K, Jury J, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut. 2006 Nov;55(11):1553-60. [PMID: 16638791]
- Foster LM, Tompkins TA, Dahl WJ. A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. Benef Microbes. 2011 Dec 1;2(4):319-34. [PMID: 22146691]
- Ivanko O. Lacidofil in the prevention of Clostridium difficile diarrhea in children. Zaporozhye State Medical University, Ukraine. Unpublished results. [summary on file]
- TlaskalP, Michkova H, Klayarova L, et al. [Lactobacillus acidophilus in the treatment of children with gastrointestinal tract illnesses] [in Chez]. CeskoSlovenska Pediatrie. 1995;51:615-19. [translation on file]
- Ziemniak W. Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:123-41. [PMID: 17033111]
- Song HJ, Kim JY, Jung SA, et al. Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. J Korean Med Sci. 2010 Dec;25(12):1784-91. [PMID: 21165295]
Serving Size: 2 Capsules
Take one to two capsules one to three times a day, or as directed by your healthcare practitioner.
Other Ingredients: Maltodextrin, gelatin (capsule), magnesium stearate, and ascorbic acid.